Quick Answer
Milestone Pharmaceuticals Inc. reported R&D Expense of $18.11 million for fiscal year 2025.
Milestone Pharmaceuticals Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $18.11M | +26.1% |
| 2024 | $14.36M | -53.8% |
| 2023 | $31.05M | -22.0% |
| 2022 | $39.83M | +3.0% |
| 2021 | $38.67M | +12.1% |
| 2020 | $34.49M | -17.9% |
| 2019 | $41.98M | +149.2% |
| 2018 | $16.85M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.94M | -0.6% | +7.4% |
| June 30, 2025 | $3.67M | +30.3% | -26.3% |
| March 31, 2025 | $4.98M | +36.8% | +25.6% |
| September 30, 2024 | $3.96M | -41.0% | +40.8% |
| June 30, 2024 | $2.81M | -67.4% | -22.6% |
| March 31, 2024 | $3.64M | -64.5% | -45.9% |
| September 30, 2023 | $6.72M | -31.6% | -22.0% |
| June 30, 2023 | $8.62M | -19.1% | -15.9% |
- Milestone Pharmaceuticals Inc. showed an increase of +26.1% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Milestone Pharmaceuticals Inc.’s r&d expense has grown by 7.5% (from $16.85 million to $18.11 million).
- The most recent figure is from Milestone Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: